![](https://investorshub.advfn.com/uicon/696558.png?cb=1610819692)
Wednesday, March 10, 2021 10:26:17 PM
Question for our Pharma docs on the board: There seems to be a pretty high obsession on SI the past couple days. I'm reading up on it...how accurate is my understanding of the following:
SI = Selectivity Index
AVA = Antiviral Activity
TOX = Cytotoxicity
SI = AVA/TOX
Brilacidin is considerably safer than most of the drugs on this list from a cytotoxicity perspective. Therefore it has a relatively (very) low TOX value compared to many of these other drugs.
Take some possible numbers:
Remdesivir AVA = 1032
Remdesivir TOX = 8
Brilacidin AVA = 213
Brilacidin TOX = 0.5
Remdesivir SI = 1032/8 = 129
Brilacidin SI = 213/0.5 = 426
So there is a potential set of numbers where Brilacidin has a much higher SI while having a much lower AVA because the TOX value is extremely low comparatively. Brilacidin dosage is limited by systemic blood pressure effects rather than cytotoxicity. Therefore it seems like the truth about how valuable SI is depends on what the underlying variables actually are.
The question the trial will answer is does Brilacidin have ample effect on COVID at dosages below the problematic ones of the Polymedix trial. If so, we have a hit, If not, the situation becomes more precarious. SI is the same in either case.
I'm not sure how useful SI is for Brilacidin. I think Brilacidin will kill the patient through systemic damage (Polymedix+ SAEs) long before it has a cytotoxic (cell damage) dosage.
Obviously all things equal a higher SI is better than a lower one but in the case of Brilacidin isn't our dosage limitation based on systemic SAE constraints rather than cytotoxicity?
Go IPIX!
Brilacidin: To COVID. From Russia with love.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM